# PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Kisqali and Kisqali Femara Co-Pack Prior Authorization Policy
- Kisqali® (ribociclib tablets – Novartis)
- Kisqali® Femara® Co-Pack (ribociclib tablets; letrozole tablets – Novartis)

**REVIEW DATE:** 02/21/2024

---

***INSTRUCTIONS FOR USE***

*THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.*

## CIGNA NATIONAL FORMULARY COVERAGE:

## OVERVIEW

Kisqali, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative **advanced or metastatic breast cancer** in adults in the following settings:[1-3]

- In combination with an aromatase inhibitor (AI) as initial endocrine-based therapy;
- Kisqali (not Co-Pack) in combination with fulvestrant as initial endocrine based therapy or following disease progression on endocrine therapy in postmenopausal women or in men;
- Kisqali Femara Co-Pack has the same indication with AI, letrozole, included.

## Guidelines

Kisqali is discussed in in guidelines from National Comprehensive Cancer Network (NCCN):

- **Breast Cancer**: NCCN guidelines (version 1.2024 – January 25, 2024) recommends Kisqali + AI or fulvestrant as a first-line "Preferred Regimen" for HR+ and HER2-negative recurrent unresectable (local or regional) or Stage IV

disease in postmenopausal women or premenopausal patient receiving ovarian ablation or suppression (category 1).[3,4] The guidelines state in a footnote that in phase III randomized controlled trials, Kisqali + endocrine therapy has shown overall survival benefit in the first-line setting. CDK4/6 inhibitor + fulvestrant is recommended as a "Preferred Regimen" for second- and subsequent-line therapy, if CDK4/6 inhibitor was not previously used (category 1). However, the guidelines also state in a footnote that if there is disease progression on Ibrance® (palbociclib tablets or capsules), there are limited data to support the use of Kisqali in the second-line setting.[3,4] The guidelines state that in phase III randomized controlled trials, fulvestrant in combination with a CDK4/6 inhibitor has shown overall survival benefit in the second-line setting. For men with breast cancer, the compendium recommends they be treated similarly to postmenopausal women, except that the use of an AI is ineffective without concomitant suppression of testicular steroidogenesis.[4]

- **Endometrial Cancer**: NCCN uterine neoplasms guidelines (version 1.2024 – September 20, 2023) recommend Kisqali in combination with letrozole for recurrent or metastatic endometrial carcinoma for estrogen receptor (ER)-positive tumors (category 2A).[5]

## POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Kisqali and Kisqali Femara Co-Pack. All approvals are provided for the duration noted below. In the clinical criteria, as appropriate, an asterisk (*) is noted next to the specified gender. In this context, the specified gender is defined as follows: a woman is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression; men are defined as individuals with the biological traits of a man, regardless of the individual's gender identity or gender expression.

- **Kisqali® (ribociclib tablets ( Novartis)**
- **Kisqali® Femara® Co-Pack (ribociclib tablets; letrozole tablets ( Novartis)**

**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

### FDA-Approved Indications

1. **Breast Cancer in Women***. Approve for 1 year if the patient meets the following (A, B, C, D, E, and F):
   - **A)** Patient is ≥ 18 years of age; AND
   - **B)** Patient has recurrent or metastatic disease; AND
   - **C)** Patient has hormone receptor-positive (HR+) [i.e., estrogen receptor-positive {ER+} and/or progesterone receptor-positive {PR+}] disease; AND

**D)** Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer; AND

**E)** Patient meets ONE of the following (i or ii):

**i.** Patient is postmenopausal; OR

**ii.** Patient is pre/perimenopausal and meets one of the following (a or b):

**a)** Patient is receiving ovarian suppression/ablation with a gonadotropin-releasing hormone (GnRH) agonist; OR

Note: Examples of a GnRH agonist include leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant).

**b)** Patient has had surgical bilateral oophorectomy or ovarian irradiation; AND

**F)** Patient meets ONE of the following (i or ii):

**i.** Kisqali will be used in combination with anastrozole, exemestane, or letrozole; OR

**ii.** Kisqali will be used in combination with fulvestrant.

***** Refer to the Policy Statement.

**2. Breast Cancer in Men*.** Approve for 1 year if the patient meets the following (A, B, C, D, and E):

**A)** Patient is ≥ 18 years of age; AND

**B)** Patient has recurrent or metastatic disease; AND

**C)** Patient has hormone receptor-positive (HR+) [i.e., estrogen receptor-positive {ER+} and/or progesterone receptor-positive {PR+}] disease; AND

**D)** Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer; AND

**E)** Patient meets ONE of the following (i or ii):

**i.** Patient meets BOTH of the following (a and b):

**a)** Patient is receiving a gonadotropin-releasing hormone (GnRH) analog; AND

Note: Examples of GnRH analog include leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Firmagon (degarelix acetate subcutaneous injection), Orgovyx (relugolix tablet).

**b)** Kisqali will be used in combination with anastrozole, exemestane, or letrozole; OR

**ii.** Kisqali will be used in combination with fulvestrant.

***** Refer to the Policy Statement.

**Other Uses with Supportive Evidence**

3. **Endometrial Cancer.** Approve for 1 year if the patient meets the following (A, B, C, and D):
   **A)** Patient is ≥ 18 years of age; AND
   **B)** Patient has recurrent or metastatic disease; AND
   **C)** Patient has estrogen receptor (ER)-positive tumors; AND
   **D)** Kisqali will be used in combination with letrozole.

**II.** Coverage of Kisqali Femara Co-Pack is recommended in those who meet one of the following criteria:

**FDA-Approved Indications**

1. **Breast Cancer in Women*.** Approve for 1 year if the patient meets the following (A, B, C, D, and E):
   **A)** Patient is ≥ 18 years of age; AND
   **B)** Patient has recurrent or metastatic disease; AND
   **C)** Patient has hormone receptor-positive (HR+) [i.e., estrogen receptor-positive {ER+} and/or progesterone receptor-positive {PR+}] disease; AND
   **D)** Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer; AND
   **E)** Patient meets ONE of the following (i or ii):
      **i.** Patient is postmenopausal OR
      **ii.** Patient is pre/perimenopausal and meets one of the following (a or b):
         **a)** Patient is receiving ovarian suppression/ablation with a gonadotropin-releasing hormone (GnRH) agonist; OR
         Note: Examples of a GnRH agonist include leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant).
         **b)** Patient has had surgical bilateral oophorectomy or ovarian irradiation.

   ***** Refer to the Policy Statement.

2 **Breast Cancer in Men*.** Approve for 1 year if the patient meets the following (A, B, C, D, and E):
   **A)** Patient is ≥ 18 years of age; AND
   **B)** Patient has recurrent or metastatic disease; AND
   **C)** Patient has hormone receptor-positive (HR+) [i.e., estrogen receptor-positive {ER+} and/or progesterone receptor-positive {PR+}] disease; AND
   **D)** Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer; AND
   **E)** Patient is receiving a gonadotropin-releasing hormone (GnRH) analog.
   Note: Examples of a GnRH analog include leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant),

Firmagon (degarelix acetate subcutaneous injection), Orgovyx (relugolix tablet).

***** Refer to the Policy Statement.

**Other Uses with Supportive Evidence**

**3. Endometrial Cancer.** Approve for 1 year if the patient meets the following (A, B, and C):
**A)** Patient is ≥ 18 years of age; AND
**B)** Patient has recurrent or metastatic disease; AND
**C)** Patient has estrogen receptor (ER)-positive tumors.

## CONDITIONS NOT COVERED

- **Kisqali® (ribociclib tablets ( Novartis)**
- **Kisqali® Femara® Co-Pack (ribociclib tablets; letrozole tablets ( Novartis)**

**is(are) considered experimental, investigational or unproven for ANY other use(s).**

## REFERENCES


1. Kisqali® tablets [prescribing information]. East Hanover, NJ: Novartis; August 2023.
2. Kisqali® Femara® Co-Pack tablets [prescribing information]. East Hanover, NJ: Novartis; October 2022.
3. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (version 1.2024 – January 25, 2024). © 2024 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on February 19, 2024.
4. The NCCN Compendium. © 2024 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Search term: ribociclib. Accessed on February 19, 2024.
5. The NCCN Uterine Neoplasms Clinical Practice Guidelines in Oncology (version 1.2024 – September 20, 2023). © 2023 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on February 19, 2024.


## History

| Type of Revision | Summary of Changes | Review Date |
|---|---|---|
| Annual Revision | No criteria changes**.** | 02/22/2023 |
| Annual Revision | **Endometrial Cancer:** For Kisqali and Kisqali Femara Co-Pack, this condition and criteria for approval were added to "Other Uses with Supportive Evidence" section. | 02/21/2024 |

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management,

Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.